# A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Source: https://onco.cc/trials/nct06010329/  
OnCo record `nct06010329` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sutetinib Maleate Capsule in non-small-cell lung cancer, run by Teligene US, now recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC is a phase 2 interventional study registered as NCT06010329 by Teligene US, with 66 participants planned, started 2023-12-27 and due to reach its primary completion in 2027-12. Interventions recorded: Sutetinib Maleate Capsule.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06010329
- Phase: 2
- Setting: A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)
- Sponsor: Teligene US
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT06010329: https://clinicaltrials.gov/study/NCT06010329

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06010329.json